No Detail Found!

High-dose Chemotherapy Response in Adults with Relapsed/Refractory Small Round Cell Tumours

Author(s)
Musa Baris Aykan Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine,Ankara,Turkey
Ismail Erturk Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine,Ankara,Turkey
Ramazan Acar Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine,Ankara,Turkey
Gül Sema Yildiran Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine,Ankara,Turkey
Birol Yildiz Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine,Ankara,Turkey
Nuri Karadurmus Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine,Ankara,Turkey
Abstract
Objective: To demonstrate the treatment responses, survival analysis, and treatment-related mortality characteristics of high-dose chemotherapy (HDC) in patients with relapsed/refractory Ewing sarcoma (ES), osteosarcoma, rhabdomyosarcoma (RMS) and medulloblastoma (MB). Study Design: Observational study. Place and Duration of Study:Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, from January 2016 and April 2020. Methodology: Clinical features and follow-up data of relapsed/refractory ES, osteosarcoma, RMS and MB patients treated with HDC were recorded from the patients registration database of the hospital. Patients <16 years and those whose medical records were not available were excluded. Progression-free survival (PFS), one-year overall survival (OS) rates and treatment-related mortality (TRM) after the HDC were determined. Ifosfamide, carboplatin and etoposide (HD-ICE) were used as the HDC protocol in all patients. Results: Thirty-seven adult patients were included. PFS was determined as 2.70 ± 0.97 months, 11.57 ± 3.63 months, 3.47 ± 0.44 months and 2.96 ± 0.91 months, for ES, MB, RMS and osteosarcoma, respectively. One-year OS rate was 44.8 ± 14.8% for ES; 75 ± 15.8% for MB. In ES, PFS was found to be better in males than females (p = 0.025). No patient died during HD-ICE. Mortality was observed most frequently in the RMS in the rst 100 days (25%). Conclusion: HD-ICE treatment may be an option in relapsed/refractory small round cell tumours (SRCT). Signi cant progression-free survival can be achieved in patients who received at least two lines of treatment, with acceptable treatment-related mortality.
Publication Details
Page(s) 51-56
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Medulloblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing sarcoma, Small round cell tumours, High-dose chemotherapy, Autologous stem cell transplantation
0

Citations

0

Downloads

96

Views